Notably, synergistic anti-tumour activity was observed in an FGFR2-amplified and MET overexpressing GC patient-derived xenograft (PDX) model treated with the FGFR inhibitor AZD4547 and the MET inhibitor crizotinib, confirming the capacity of MET to confer at least partial resistance to FGFR inhibition [99]. The gene discussed is FGFR2; the disease is neoplasm.